Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlos Alves

Showing results (11-20 of 327) with videos related to

Pageof 33
Sort By:
Expert Opinion on Drug Safety|July 29, 2016
Testing the usefulness of the number needed to treat to be harmed (NNTH) in benefit-risk evaluations: case study with medicines withdrawn from the European market due to safety reasonsDiogo Mendes, Carlos Alves, Francisco Batel Marques
Acta Ophthalmologica|September 28, 2019
Risk of nonarteritic ischaemic optic neuropathy with phosphodiesterase type 5 inhibitors: a systematic review and meta-analysisAna Penedones, Carlos Alves, Francisco Batel Marques
Journal of Nursing Management|April 24, 2014
Nurses' spontaneous reporting of adverse drug reactions: expert review of routine reportsDiogo Mendes, Carlos Alves, Francisco Batel Marques
BMC Medical Research Methodology|December 13, 2019
Recommendations to conduct and report systematic reviews in medical literature: a scoping reviewAna Penedones, Carlos Alves, Francisco Batel-Marques
CNS Drugs|August 20, 2016
Benefit-Risk of Therapies for Relapsing-Remitting Multiple Sclerosis: Testing the Number Needed to Treat to Benefit (NNTB), Number Needed to Treat to Harm (NNTH) and the Likelihood to be Helped or Harmed (LHH): A Systematic Review and Meta-AnalysisDiogo Mendes, Carlos Alves, Francisco Batel-Marques
Pharmacoepidemiology and Drug Safety|October 26, 2011
Data sources on drug safety evaluation: a review of recent published meta-analysesCarlos Alves, Francisco Batel-Marques, Ana Filipa Macedo
Diabetes Research and Clinical Practice|September 27, 2012
A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancerCarlos Alves, Francisco Batel-Marques, Ana F Macedo
Journal of Clinical Medicine|January 28, 2026
Quality of Systematic Reviews with Network Meta-Analyses on JAK Inhibitors in the Treatment of Rheumatoid Arthritis: Application of the AMSTAR 2 ScaleBruna Ramalho, Ana Penedones, Diogo Mendes, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|May 12, 2026
Clinical outcomes in HTA appraisal reports of oncology medicines in Portugal: A cross-sectional analysisPedro Teodoro, Catarina Ribeiro, Diogo Mendes, et al.
European Journal of Clinical Pharmacology|April 3, 2014
Drug-safety alerts issued by regulatory authorities: usefulness of meta-analysis in predicting risks earlierCarlos Alves, Francisco Batel Marques, Ana Filipa Macedo
Pageof 33

Showing results (11-20 of 327) with videos related to

Sort By:
Pageof 33
Expert Opinion on Drug Safety|July 29, 2016
Testing the usefulness of the number needed to treat to be harmed (NNTH) in benefit-risk evaluations: case study with medicines withdrawn from the European market due to safety reasonsDiogo Mendes, Carlos Alves, Francisco Batel Marques
Acta Ophthalmologica|September 28, 2019
Risk of nonarteritic ischaemic optic neuropathy with phosphodiesterase type 5 inhibitors: a systematic review and meta-analysisAna Penedones, Carlos Alves, Francisco Batel Marques
Journal of Nursing Management|April 24, 2014
Nurses' spontaneous reporting of adverse drug reactions: expert review of routine reportsDiogo Mendes, Carlos Alves, Francisco Batel Marques
BMC Medical Research Methodology|December 13, 2019
Recommendations to conduct and report systematic reviews in medical literature: a scoping reviewAna Penedones, Carlos Alves, Francisco Batel-Marques
CNS Drugs|August 20, 2016
Benefit-Risk of Therapies for Relapsing-Remitting Multiple Sclerosis: Testing the Number Needed to Treat to Benefit (NNTB), Number Needed to Treat to Harm (NNTH) and the Likelihood to be Helped or Harmed (LHH): A Systematic Review and Meta-AnalysisDiogo Mendes, Carlos Alves, Francisco Batel-Marques
Pharmacoepidemiology and Drug Safety|October 26, 2011
Data sources on drug safety evaluation: a review of recent published meta-analysesCarlos Alves, Francisco Batel-Marques, Ana Filipa Macedo
Diabetes Research and Clinical Practice|September 27, 2012
A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancerCarlos Alves, Francisco Batel-Marques, Ana F Macedo
Journal of Clinical Medicine|January 28, 2026
Quality of Systematic Reviews with Network Meta-Analyses on JAK Inhibitors in the Treatment of Rheumatoid Arthritis: Application of the AMSTAR 2 ScaleBruna Ramalho, Ana Penedones, Diogo Mendes, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|May 12, 2026
Clinical outcomes in HTA appraisal reports of oncology medicines in Portugal: A cross-sectional analysisPedro Teodoro, Catarina Ribeiro, Diogo Mendes, et al.
European Journal of Clinical Pharmacology|April 3, 2014
Drug-safety alerts issued by regulatory authorities: usefulness of meta-analysis in predicting risks earlierCarlos Alves, Francisco Batel Marques, Ana Filipa Macedo
Pageof 33